• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

受体和抗原介导的硼中子俘获治疗中的辐射剂量异质性

Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy.

作者信息

Hartman T, Carlsson J

机构信息

Department of Radiation Sciences, Uppsala University, Sweden.

出版信息

Radiother Oncol. 1994 Apr;31(1):61-75. doi: 10.1016/0167-8140(94)90414-6.

DOI:10.1016/0167-8140(94)90414-6
PMID:8041899
Abstract

Boron neutron capture therapy, BNCT, might be a valuable tumour therapeutical modality for the treatment of cells that are difficult to handle with conventional methods such as surgery or external radiotherapy. The principle is that tumour associated 10B atoms capture thermal neutrons and thereby forms high-LET helium and lithium ions as reaction products. An interesting development is to conjugate 10B atoms to macromolecules that bind to tumour cells with over-expressed receptors or specific antigens. The targeting macromolecules might be receptor-ligands, antibodies or antibody-fragments containing 10B. The present study deals with the limitations of such an approach. One problem is the background dose from capture of neutrons in physiologically occurring elements, especially nitrogen. We showed, with computer simulations, that the background specific energy (the stochastic analogy of dose) in the cell nuclei, due to captures in nitrogen, had a wide spread and could be rather high, up to 3 Gy in some cells, when relevant neutron fluencies were applied. The maximal amount of 10B that can be delivered to single tumour cells due to receptor-ligand, receptor-antibody or antigen-antibody mediated binding is probably in the range 10(8)-10(10) atoms/cell. Our calculations showed that the tumour cells had to contain about 10(9) 10B/cell to give a therapeutically interesting dose to the nuclei of the targeted cells. The doses were highest when the boron was in the cell nucleus. There was also a wide spread of specific energy absorbed by the nuclei after neutron capture in 10B. When, for example, 10(8) 10(10)B/nucleus were applied the specific energy to the analysed nuclei varied from 0 Gy up to about 7 Gy. These variations were due to the stochastic nature of the capture processes. Some helium or lithium ion tracks passed through the centre of the cell nuclei delivering a lot of energy, some passed through only a smaller part delivering small amounts of energy and sometimes the nuclei escaped without any hits at all. The results were obtained when relevant neutron fluencies (2-5 x 10(12) n/cm2) were applied. Increased neutron fluencies gave higher doses both due to capture in boron and in nitrogen but in order to improve the ratio between the dose to targeted tumour cells and the dose to normal cells, the number of 10B atoms in the targeted cells had to be increased and/or the boron placed in the cell nuclei.

摘要

硼中子俘获疗法(BNCT)可能是一种有价值的肿瘤治疗方式,可用于治疗难以用手术或外部放射疗法等传统方法处理的细胞。其原理是肿瘤相关的硼 - 10原子俘获热中子,从而形成高传能线密度的氦离子和锂离子作为反应产物。一个有趣的进展是将硼 - 10原子与能与过表达受体或特异性抗原结合的肿瘤细胞的大分子偶联。靶向大分子可能是受体 - 配体、抗体或含硼 - 10的抗体片段。本研究探讨了这种方法的局限性。一个问题是生理存在元素(尤其是氮)俘获中子产生的本底剂量。我们通过计算机模拟表明,由于氮俘获,细胞核中的本底比能(剂量的随机类似物)分布广泛且可能相当高,当应用相关中子注量时,某些细胞中可达3戈瑞。由于受体 - 配体、受体 - 抗体或抗原 - 抗体介导的结合,可递送至单个肿瘤细胞的硼 - 10的最大量可能在10⁸ - 10¹⁰个原子/细胞范围内。我们的计算表明,肿瘤细胞必须含有约10⁹个硼 - 10/细胞,才能给靶向细胞的细胞核提供具有治疗意义的剂量。当硼在细胞核中时剂量最高。硼 - 10俘获中子后,细胞核吸收的比能也有广泛分布。例如,当应用10⁸ - 10¹⁰个硼 - 10/核时,分析细胞核的比能从0戈瑞变化到约7戈瑞。这些变化是由于俘获过程的随机性。一些氦或锂离子径迹穿过细胞核中心传递大量能量,一些只穿过较小部分传递少量能量,有时细胞核根本未被击中。这些结果是在应用相关中子注量(2 - 5×10¹² n/cm²)时获得的。增加中子注量会因硼和氮的俘获而产生更高剂量,但为了提高靶向肿瘤细胞剂量与正常细胞剂量的比值,必须增加靶向细胞中硼 - 10原子的数量和/或将硼置于细胞核中。

相似文献

1
Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy.受体和抗原介导的硼中子俘获治疗中的辐射剂量异质性
Radiother Oncol. 1994 Apr;31(1):61-75. doi: 10.1016/0167-8140(94)90414-6.
2
Dose enhancement in fast neutron tumour therapy due to neutron captures in 10B.硼-10 中的中子俘获导致快中子肿瘤治疗中的剂量增强。
Acta Oncol. 1994;33(3):315-22. doi: 10.3109/02841869409098423.
3
Boron neutron capture therapy for malignant gliomas.硼中子俘获疗法治疗恶性胶质瘤。
Ann Med. 2000 Feb;32(1):81-5. doi: 10.3109/07853890008995913.
4
In vitro determination of toxicity, binding, retention, subcellular distribution and biological efficacy of the boron neutron capture agent DAC-1.硼中子俘获剂DAC-1的毒性、结合、滞留、亚细胞分布及生物学效应的体外测定
Radiother Oncol. 1996 Jan;38(1):41-50. doi: 10.1016/0167-8140(95)01633-3.
5
The effectiveness of the high-LET radiations from the boron neutron capture [10B(n,α) 7Li] reaction determined for induction of chromosome aberrations and apoptosis in lymphocytes of human blood samples.通过硼中子俘获[¹⁰B(n,α)⁷Li]反应产生的高传能线密度辐射对人血样本淋巴细胞中染色体畸变和细胞凋亡诱导作用的有效性已得到确定。
Radiat Environ Biophys. 2015 Mar;54(1):91-102. doi: 10.1007/s00411-014-0577-y. Epub 2014 Nov 27.
6
Present status of boron neutron capture therapy.硼中子俘获疗法的现状
Acta Oncol. 1992;31(8):803-13. doi: 10.3109/02841869209089712.
7
Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor.硼中子俘获疗法(BNCT)治疗恶性黑色素瘤,特别提及正常皮肤和肿瘤的吸收剂量。
Australas Phys Eng Sci Med. 2003 Sep;26(3):97-103. doi: 10.1007/BF03178777.
8
Monte Carlo simulation of the biological effects of boron neutron capture irradiation with d(14)+Be neutrons in vitro.体外d(14)+Be中子硼中子俘获辐照生物效应的蒙特卡罗模拟
Radiat Res. 1995 Apr;142(1):98-106.
9
Boron neutron capture therapy of brain tumors: an emerging therapeutic modality.脑肿瘤的硼中子俘获疗法:一种新兴的治疗方式。
Neurosurgery. 1999 Mar;44(3):433-50; discussion 450-1. doi: 10.1097/00006123-199903000-00001.
10
Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory.利用布鲁克海文国家实验室的超热中子束对多形性胶质母细胞瘤(GBM)进行硼中子俘获治疗(BNCT)。
Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):829-34. doi: 10.1016/s0360-3016(97)00891-2.

引用本文的文献

1
Unlocking the potential: phenylboronic acid as a nuclear-targeting boron agent for neutron capture therapy.发挥潜力:苯硼酸作为用于中子俘获治疗的核靶向硼试剂。
Med Oncol. 2024 Apr 4;41(5):104. doi: 10.1007/s12032-024-02351-3.
2
New Boron Containing Acridines: Synthesis and Preliminary Biological Study.新型含硼吖啶类化合物的合成与初步生物学研究。
Molecules. 2023 Sep 15;28(18):6636. doi: 10.3390/molecules28186636.
3
Therapeutic nucleus-access BNCT drug combined CD47-targeting gene editing in glioblastoma.治疗性核内 BNCT 药物联合 CD47 靶向基因编辑治疗胶质母细胞瘤。
J Nanobiotechnology. 2022 Mar 4;20(1):102. doi: 10.1186/s12951-022-01304-0.
4
Boron rich nanotube drug carrier system is suited for boron neutron capture therapy.富硼纳米管药物载体系统适合硼中子俘获疗法。
Sci Rep. 2021 Jul 30;11(1):15520. doi: 10.1038/s41598-021-95044-0.
5
Design, Synthesis, and Biological Evaluation of Boron-Containing Macrocyclic Polyamines and Their Zinc(II) Complexes for Boron Neutron Capture Therapy.含硼大环多胺及其锌(II)配合物的设计、合成与硼中子俘获治疗的生物学评价。
J Med Chem. 2021 Jun 24;64(12):8523-8544. doi: 10.1021/acs.jmedchem.1c00445. Epub 2021 Jun 2.
6
Modular Synthetic Approach to Carboranyl‒Biomolecules Conjugates.模块化合成方法构建碳硼烷-生物分子缀合物。
Molecules. 2021 Apr 3;26(7):2057. doi: 10.3390/molecules26072057.
7
Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies.肽-药物偶联物及其在晚期癌症治疗中的靶点
Front Chem. 2020 Jul 7;8:571. doi: 10.3389/fchem.2020.00571. eCollection 2020.
8
Remarkable Boron Delivery Of iRGD-Modified Polymeric Nanoparticles For Boron Neutron Capture Therapy.iRGD 修饰的聚合物纳米粒子用于硼中子俘获治疗的硼的递送效果显著。
Int J Nanomedicine. 2019 Oct 8;14:8161-8177. doi: 10.2147/IJN.S214224. eCollection 2019.
9
Enlargement of a Modular System-Synthesis and Characterization of an -Triazine-Based Carboxylic Acid Ester Bearing a Galactopyranosyl Moiety and an Enormous Boron Load.基于三嗪的羧酸酯的模块化系统合成与表征 - 具有半乳糖吡喃基部分和巨大硼载量的
Molecules. 2019 Sep 10;24(18):3288. doi: 10.3390/molecules24183288.
10
Radionuclide carriers for targeting of cancer.用于癌症靶向的放射性核素载体
Int J Nanomedicine. 2008;3(2):181-99. doi: 10.2147/ijn.s2736.